April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Impact of Glaucoma Type on the Success of Transscleral Diode Laser Cyclophotocoagulation in the Treatment of Refractory Glaucoma
Author Affiliations & Notes
  • Samantha S Dewundara
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Bret Hughes
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Saya Nagori
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Aman Shukairy
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Justin Tannir
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Anju Goyal
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Mark S Juzych
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Chaesik Kim
    Ophthalmology, Kresge Eye Institute, Detroit, MI
  • Footnotes
    Commercial Relationships Samantha Dewundara, None; Bret Hughes, None; Saya Nagori, None; Aman Shukairy, None; Justin Tannir, None; Anju Goyal, None; Mark Juzych, None; Chaesik Kim, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6166. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Samantha S Dewundara, Bret Hughes, Saya Nagori, Aman Shukairy, Justin Tannir, Anju Goyal, Mark S Juzych, Chaesik Kim; Impact of Glaucoma Type on the Success of Transscleral Diode Laser Cyclophotocoagulation in the Treatment of Refractory Glaucoma. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6166.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: This study was conducted to evaluate the impact of the type of glaucoma on the success of treatment with transscleral diode laser cyclophotocoagulation (TSDLCP) in refractory glaucoma.

Methods: This retrospective study analyzed 90 eyes in 90 patients with glaucoma refractory to conventional medical and/or surgical management and thereafter treated with TSDLCP. With respect to type of glaucoma, 43 eyes with chronic open angle glaucoma (OAG), 25 eyes with chronic angle-closure glaucoma (ACG) and 22 eyes with neovascular glaucoma (NVG) were studied. Success in treatment was defined as IOP measured between 5-22mmHg with no increase in number of antiglaucoma medications and no additional diode or incisional surgery.

Results: Mean follow up for patients with OAG was 13±2 months, ACG 19±3 months and 8±1 months for NVG. There was no statistically significant difference in total energy delivered per eye and patients of all three groups received 20 ± 6 laser applications per session, each lasting 2 seconds in duration, ranging from 180-360 degrees. Patients received one treatment session per eye. Mean pretreatment IOP was 34.6±10.1mmHg for OAG, 37.6±10.1mmHg for ACG and 38.9±12.3mmHg for NVG (P>0.05). At 24 months follow up, mean post-treatment IOP was significantly reduced across all types of glaucoma. Mean post-treatment IOP at 24 months was 18.1±8.8mmHg for OAG, 25.0±12.3mmHg for ACG and 22.4±9.0mmHg for NVG (P>0.05). There was no statistically significant difference in the IOP lowering effect of TSDLCP across the different types of glaucoma and all follow up time points. At 15 months follow up, a success of 39% was noted for eyes with OAG, 53% for ACG and 17% for NVG. Of the ten eyes requiring additional incisional surgery, 60% of those eyes had NVG (P<0.05).

Conclusions: With significant reductions in IOP, TSDLCP is an effective treatment for refractory glaucoma, independent of glaucoma type. When assessing success of treatment in a clinical setting, ACG yielded the best results, followed by OAG and then NVG. Interestingly, of patients requiring additional incisional surgical intervention, eyes with NVG were more common.

Keywords: 558 inflow/ciliary body • 568 intraocular pressure • 578 laser  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×